Cancer clinical trials in the region Auvergne-Rhône-Alpes

509 currently recruiting clinical trials
Region Auvergne-Rhône-Alpes
Phase 3 Multiple myeloma #NCT07665450
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
2 recruiting sites
Janssen
Phase 3 Breast cancer #NCT05696626 #2023-503708-10-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ESR
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Targeted therapy Hormone therapy
Excluded genetic anomalies
Other mutation
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Sermonix Pharmaceuticals Inc.
Phase 3 Lung cancer #NCT06345729 #2023-507776-42-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KRAS G12C
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Breast cancer #NCT07205822
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy
5 recruiting sites
AstraZeneca
Phase 3 Multiple myeloma #NCT07258511 #2025-522007-18-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
3 or more
Required previous treatments
Monoclonal antibodies Proteasome inhibitor Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
10 recruiting sites
Janssen
Phase 3 Rectal cancer #NCT03875781 #2024-510580-28-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Radiotherapy
Excluded previous treatments at advanced or metastatic stage
Radiotherapy
8 recruiting sites
Assistance Publique - Hôpitaux de Paris
Phase 3 Colon cancer Rectal cancer Pancreas cancer Stomach and esophageal cancer #NCT06937905 #2024-515948-23-00
Required histologic sub types
Neuroendocrine carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
42 recruiting sites
Intergroupe Francophone de Cancérologie Thoracique
Phase 3 Breast cancer #NCT07060807
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None 1
Required previous treatments at localized stage
Targeted therapy Hormone therapy
Required previous treatments at advanced or metastatic stage
Targeted therapy Hormone therapy
Excluded previous treatments at localized stage
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy Antibody Drug Conjugates (ADC)
4 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Lung cancer #NCT07099898 #2025-521627-78
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
4 recruiting sites
GlaxoSmithKline
Phase 3 Skin cancer #NCT06264180
Required histologic types
Melanoma
Required histologic sub types
Nodular melanoma Lentigo maligna melanoma Superficial spreading melanoma Acral lentiginous melanoma Achromic melanoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
BRAF
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Replimune